Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus VDC/IE for newly diagnosed metastatic Ewing sarcoma
NL-OMON58740Phase 1Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in Ewing sarcoma, sponsored by Gustave Roussy. Primary endpoint: Dose-limiting toxicity. Started Dec 2023; status: active, not recruiting.
02
Drugs
regorafenib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NL-OMON58740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58740.